Why heavy metals and toxic and must be taken into consideration when being treated for cancer.
Heavy metals are some of the most well-known toxins. They include the big guns: Lead, Mercury, Aluminum and the #1 substance on the Agency for Toxic Substances and Disease Registry (ATSDR) toxin priority list—Arsenic. Heavy metals are:
- Mutagenic (which is in and of itself carcinogenic)
In addition to their toxicity, all have been shown to have estrogenic activity and thus have been labeled metalloestrogens. Think of that, a heavy metal that has estrogenic activity. Not only are they toxic, but they are hormonal.
How is this possible? Studies have shown these heavy metals exert their estrogenic activity through direct binding to estrogen receptors; ER-alpha to be exact. This affinity is so strong that these metals will even block estradiol (the most potent estrogen) from binding.
Through the estrogen receptors, metals will provide direct genomic signaling via what are called Estrogen Response Elements (ERE) and non-genomic signaling via activation of the well-known pro-growth signaling pathway proteins, activated in most cancers, of ERK (of the famous RAS-RAF-MEK-ERK pathway) and PI3K/Akt that interacts with mTOR.
Heavy Metals And Cancer Explained By Dr. Nathan Goodyear
Both pathways are uniformly unregulated in most types of cancers. In addition, the heavy metal cadmium has been shown to block the repair of damaged DNA .
One heavy metal that stands head and shoulders above the rest is cadmium. Cadmium is the most well-known metalloestrogen. The half-life of cadmium is an astonishing 20 years. Cigarette smoking and welding are the 2 most prominent sources of cadmium exposure.
In vitro and In vivo studies of cadmium have shown cadmium increases the cancer risk of the estrogen-sensitive uterus , breast   and prostate   organs. Even cadmium’s strong link to lung cancer is through estrogen receptor signaling . The more we know, the more we realize we don’t know.
In so many cases, the source of estrogen exposure or estrogen signaling is not through endogenous estrogen production or even through Hormone Replacement Therapy (HRT), but via these environmental estrogen-mimicking compounds. The next example of some of these estrogen-mimicking compounds are the mycotoxins.
33 McElroy JA, Kruse RL, Guthrie J, Gangnon RE, Robertson JD. Cadmium exposure and endometrial cancer risk: A large midwestern U.S. population-based case-control study. PLoS One. 2017;12(7):e0179360. Published 2017 Jul 24. doi:10.1371/journal.pone.0179360
37 Rapisarda V, Miozzi E, Loreto C, Matera S, Fenga C, Avola R, Ledda C. Cadmium exposure and prostate cancer: insights, mechanisms, and perspectives. Frontiers In Bioscience, Landmark. Mar 1 2018;23:1687-1700.
38 Mary O. Huff, Sarah L. Todd, Aaron L. Smith, Julie T. Elpers, Alexander P. Smith, Robert D. Murphy, Allison S. Bleser-Shartzer, Jacob E. Hoerter, Brandie N. Radde, Carolyn M. Klinge, Arsenite and Cadmium Activate MAPK/ERK via Membrane Estrogen Receptors and G-Protein Coupled Estrogen Receptor Signaling in Human Lung Adenocarcinoma Cells, Toxicological Sciences, Volume 152, Issue 1, July 2016, Pages 62–71, https://doi.org/10.1093/toxsci/kfw064
Dr. Nathan Goodyear is dedicated to disease prevention, disease resolution, and the Wellness Lifestyle through a solution-based, Integrative Medicine approach founded in science. Dr. Goodyear received his Bachelor of Arts from Louisiana Tech University and his Doctor of Medicine from LSU Health Sciences Center.
He is Board Certified in Obstetrics and Gynecology and served as the Chief Resident in Obstetrics and Gynecology at the University of Tennessee. Dr. Goodyear has practiced Integrative Medicine since 2006. Dr. Goodyear is a Fellow in Functional and Regenerative Medicine and served on the board of the American Functional Medicine Association. Dr. Goodyear is a published author, Man Boob Nation–an Integrative medicine approach to low Testosterone published in 2014, and Total Testosterone Transformation published in 2017